Bayer's admission of 'mistake' underscores FDA's struggles

Share this content:
A Bayer admission that it "mistakingly" did not submit new risk information to the FDA on antibleeding drug Trasylol underscores the agency's struggle to get critical drug safety information out to the public. FDA had to replace a news release hours after it was issued to reflect new data.
Share this content:
Scroll down to see the next article